

Contents

| | | |
|-------------------------|--|-----|
| 1 | Genetics and Classification of Acute Myeloid Leukemia | 1 |
| | Alison R. Walker and Guido Marcucci | |
| 2 | The Use of “Omics” to Guide the Selection of Targeted Therapy | 27 |
| | Steven M. Kornblau | |
| Part I Apoptosis | | |
| 3 | Roles of Apoptosis-Regulating Bcl-2 Family Genes in AML | 47 |
| | John C. Reed | |
| 4 | Bcl-2 Family: Translational Aspects | 67 |
| | Prithviraj Bose and Steven Grant | |
| 5 | IAP Family of Proteins as Therapeutic Targets for Acute Myeloid Leukemia | 95 |
| | Bing Z. Carter and Michael Andreeff | |
| 6 | TP53 Mutations in Acute Myeloid Leukemia | 123 |
| | Ulrike Bacher, Claudia Haferlach, Vera Grossmann, Susanne Schnittger and Torsten Haferlach | |
| 7 | Targeting p53 Tumor Suppressor for AML Therapy | 135 |
| | Kojima Kensuke and Lyubomir T. Vassilev | |
| 8 | AML-Selective Apoptosis Induction by Rationally Designed Death Ligand Fusion Proteins | 151 |
| | Edwin Bremer and Wijnand Helfrich | |

Part II Signaling

| | |
|--|-----|
| 9 PIM Kinases in AML | 177 |
| Lisa S. Chen and Varsha Gandhi | |
| 10 Development of Midostaurin as a Tyrosine Kinase Inhibitor | 201 |
| Gabriela Motyckova and Richard M. Stone | |
| 11 FLT3 in AML | 215 |
| Naval Daver and Farhad Ravandi | |
| 12 FLT3-ITD. Clinical (Sorafenib/AC220) | 233 |
| Naveen Pemmaraju and Jorge Eduardo Cortes | |
| 13 Nucleophosmin (NPM1) | 251 |
| Ramesh Balusu, Warren Fiskus and Kapil N. Bhalla | |
| 14 Raf/MEK/ERK Signaling | 275 |
| James A. McCubrey, Linda S. Steelman, Jörg Bäsecke and Alberto M. Martelli | |
| 15 The Role of Translational Medicine in Optimization of Therapies Targeting the RAS-MAP Kinase Pathway | 307 |
| Judith S. Sebolt-Leopold | |
| 16 Clinical Use of Farnesyltransferase Inhibitors | 325 |
| Chezi Ganzel and Jacob M. Rowe | |
| 17 The PI3K-AKT-mTOR Signaling Network in AML | 335 |
| Brandon Beagle and David A. Fruman | |
| 18 Targeting the PI3 Kinase-mTOR Signaling Pathway in AML | 363 |
| Martin Carroll | |
| 19 Aurora Kinases | 371 |
| Subrata Sen and Hiroshi Katayama | |
| 20 The Clinical Development of Aurora Kinase Inhibitors in Acute Myeloid Leukemia | 391 |
| Kevin R. Kelly, Ciara L. Freeman and Francis J. Giles | |

Part III Epigenetics

| | |
|---|-----|
| 21 AML: Deacetylases | 411 |
| Margherita Ghisi and Ricky W. Johnstone | |

| | |
|--|-----|
| 22 Methylation in AML: Clinical Applications | 441 |
| Naveen Pemmaraju, Guillermo Garcia-Manero and Farhad Ravandi | |

Part IV Nuclear Receptors

| | |
|--|-----|
| 23 PML/RARA as the Master Driver of APL Pathogenesis and Therapy Response | 461 |
| Hugues de Thé, Jun Zhu, Rihab Nasr, Julien Ablain and Valérie Lallemand-Breitenbach | |

| | |
|---|-----|
| 24 Arsenic Trioxide in Untreated APL | 477 |
| Elihu Estey | |

| | |
|---|-----|
| 25 Targeting PML-RARα with Retinoids | 489 |
| Eytan M. Stein and Martin S. Tallman | |

| | |
|---|-----|
| 26 NR4A Orphan Receptors as Drug Targets | 509 |
| Stephen Safe, Syng-Ook Lee, Cong Meng and Beiyan Zhou | |

Part V Cell Surface Receptors

| | |
|--|-----|
| 27 Antibody-Based Therapeutics Targeting CD33, CD45, and CD66 | 531 |
| Roland B. Walter, Oliver W. Press and Irwin D. Bernstein | |

Part VI Stem Cells

| | |
|--|-----|
| 28 New Heterogeneity of the Leukemic Stem Cells | 559 |
| Dominique Bonnet | |

| | |
|---|-----|
| 29 Targeting Leukemia Stem Cells | 573 |
| Duane C. Hassane and Monica L. Guzman | |

Part VII Microenvironment

| | |
|---|-----|
| 30 Regulation of Hematopoiesis by CXCL12/CXCR4 Signaling | 593 |
| Daniel C. Link | |

| | |
|--|-----|
| 31 CXCR4/CXCL12 as a Therapeutic Target | 607 |
| Geoffrey L. Uy and John F. DiPersio | |

| | |
|---|-----|
| 32 VLA-4: A Cell's Consequential Encounter | 617 |
| Thalia Papayannopoulou | |

| | |
|--|-----|
| 33 VLA-4 Function and Prognosis in Acute Myeloid Leukemia | 627 |
| Pamela S. Becker and Frederick R. Appelbaum | |

34 VLA4 in Acute Lymphoblastic Leukemia..... 637
Halvard Bönig and Yong-Mi Kim

Part VIII Hypoxia

35 The Leukemic Bone Marrow Microenvironment: Targeting Hypoxia with Hypoxia-Activated Prodrugs 657
Juliana Benito, Marina Konopleva and William R. Wilson

Part IX Micro-RNAs

36 MicroRNAs as Therapeutic Targets..... 683
Maitri Y. Shah and George A. Calin

37 Clinical Implications of MicroRNAs in AML..... 699
Parvathi Ranganathan and Ramiro Garzon

Part X Metabolism

38 Inhibition of Glycolysis as a Therapeutic Strategy in Acute Myeloid Leukemias..... 709
Rob C. Laister, Mark D. Minden and Tak W. Mak

39 Molecular and Biochemical Basis for the Reprogramming of Intermediary Metabolism in Leukemia Cells 725
Ismael Samudio and Juliana Vélez

Part XI Cell Therapy

40 NK-Cell Immunotherapy for AML 737
Dean Anthony Lee, Laurence James Neil Cooper and Elizabeth J. Shpall

41 Allogeneic and Autologous T-cell Strategies to Enhance Targeting of Acute Myeloid Leukemias 757
Gerrit Weber, Catherine M. Bollard and A. John Barrett

42 Indications for Hematopoietic Transplantation for AML..... 777
Sairah Ahmed and Richard Champlin

43 Mesenchymal Stem/Stromal Cell-Targeted Therapies for Solid Tumors and Hematological Malignancies 799
Christopher H. Booth, Lysette Mutkus, Karen Bussard, Erika Spaeth, Michael Andreeff and Frank C. Marini

Index..... 821



<http://www.springer.com/978-1-4939-1392-3>

Targeted Therapy of Acute Myeloid Leukemia

Andreeff, M. (Ed.)

2015, XIX, 826 p. 62 illus., 46 illus. in color., Hardcover

ISBN: 978-1-4939-1392-3